Recently, Hengrui Pharmaceutical received the "Drug Registration Certificate" approved and issued by the State Drug Administration, approving the launch of the company's independently developed Tagelidine Fumarate Injection (Asut®) for the treatment of moderate to severe pain after abdominal surgery. This product is China's first independently developed innovative Class 1 opioid analgesic drug and will provide new treatment options for patients suffering from postoperative pain. So far, Hengrui has got marketing approval for 16 innovative drugs.

Postoperative pain is one of the most common forms of acute pain. It is reported that in China the prevalence of moderate to severe acute pain after surgery in patients is as high as 48.7%. At the same time, patients with moderate to severe pain are not satisfied with analgesic treatment, with 28.5% of patients expressing a need for more efficient analgesic therapy1. Taglidine Fumarate Injection is Hengrui’s key milestone product in the field of pain management. Once launched, it is expected to improve the recovery progress and quality of life of patients with postoperative pain.

As an innovative international pharmaceutical company, Hengrui Pharmaceutical has been deeply practicing its mission of “technology-based and creating a healthy life for mankind” for many years. In addition to deeply exploring the field of oncology with its traditional advantages, the company is also engaged in metabolic diseases, autoimmune diseases, respiratory diseases, etc. We continue to make efforts in the fields of systemic diseases, neurological diseases, cardiovascular diseases, infectious diseases, blood diseases, pain management, ophthalmology and other chronic diseases, and continue to enrich the layout of innovative drugs.

In the field of analgesia and anesthesia, Hengrui focuses on unmet clinical needs and actively deploys R&D pipelines, striving to bring new hope to patients. In December 2019, the company's innovative drug remimazolam tosylate for injection (Rebenin®) was launched. The launch of taglidine fumarate injection marks the company's Class 1 innovative drug in the field of analgesia and anesthesia increases to 2 styles. In December 2023, the marketing authorization application for taglidine fumarate injection for the treatment of moderate to severe pain after orthopedic surgery has also been accepted by the State Drug Administration. At the same time, the company has several products in this field undergoing clinical trials.

In recent years, Hengrui Medicine has been building a new pattern of high-quality development with more and more innovative achievements. At present, the company has obtained domestic marketing approval for 16 Class 1 innovative drugs and 4 self-developed Class 2 new drugs. In addition, more than 80 independent innovative products are under clinical development, and more than 270 clinical trials have been conducted at home and abroad. In the future, Hengrui will continue to accelerate the research and development of innovative drugs, and be committed to launching more new and good drugs to serve a healthy China and benefit patients around the world.

https://www.hengrui.com/media/detail-497.html